Trial site
Azienda Sanitaria Locale 2 Lanciano Vasto Chieti
- 16running trials
- 8closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Conditions
- Macular degeneration6 trials
- Psoriatic arthritis3 trials
- Chronic kidney disease2 trials
- Glaucoma2 trials
- Obesity2 trials
- Atrial fibrillation1 trial
- Bladder cancer1 trial
- Depression1 trial
- Heart failure1 trial
- High blood pressure1 trial
- Insomnia1 trial
- Kidney cancer1 trial
- and 5 more
- Phase
- Phase 322 trials
- Phase 22 trials
- Status
- Completed8 trials
- Recruiting8 trials
- Active, not recruiting7 trials
- Not yet recruiting1 trial
- Lead sponsor
- Boehringer Ingelheim3 trials
- Hoffmann-La Roche3 trials
- AbbVie2 trials
- Amgen2 trials
- Eli Lilly and Company2 trials
- and 12 more
Running trials
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Active, not recruiting
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Active, not recruiting
Enrolling by invitation
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
Active, not recruiting
STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS
Recruiting
Active, not recruiting
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Psoriatic arthritis3 recruiting
- Macular degeneration2 recruiting
- Heart failure1 recruiting
- High blood pressure1 recruiting
- Obesity1 recruiting
- Prostate cancer1 recruiting
- Rheumatoid arthritis1 recruiting
- Type 2 diabetes1 recruiting
Closed trials
Completed
Completed
Completed
Completed
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Completed
Completed
Active, not recruiting
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 19 Nov 2026